To address scalability challenges of AAV manufacturing, we developed an HEK293 suspension cell line that can be used across many serotypes. Get the data in this article.
This article explores a variety of lentivirus harvest clarification options and items for consideration during manufacturing platform development of viral therapy production using suspension cell lines.
Whether you are developing cell and gene therapies or viral vaccines, removing contaminating nucleic acids is an important part of viral production. The simplest way to do this is to use the Benzonase® endonuclease.
See how the Sf9 rhabdovirus-free cell line was developed and how we’ve developed a companion chemically-defined insect cell media for protein and viral expression.
Optimizing the upstream portion of gene therapy production sets the stage for successful manufacturing by maximizing viral vector titers. To increase upstream titers and process productivity, manufacturers must partner with upstream technology experts who work with HEK293, HEK293T and Sf9
This page describes key considerations for cell lysis and how the combination of a high salt concentration and a salt tolerant endonuclease can be used to increase vector titer and infectivity during AAV vector manufacturing.
Minimize the complexities of cell and gene therapy production. Switch to upstream viral vector platforms to enhance scalability and simplify GMP manufacturing.
Scaling up viral vector production using adherent cell culture systems is challenging. Learn how suspension cell culture systems benefit large-scale bioprocessing.
Learn how the VirusExpress® lentivirus platform utilizes DoE experiments and supplementary studies to optimize workflows, enhance yield, and ensure quality in cell and gene therapies.
Explore strategies for separating empty and filled capsids in viral vector production. Learn about upstream strategies and how trends in AAV capsid design impact purification.